Dr Bardia discusses data from DESTINY-Breast03, HER2CLIMB, and NALA, important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Daiichi Sankyo, we had the pleasure of speaking with Aditya Bardia, MD, MPH, an assistant professor of medicine at Harvard Medical School and a medical oncologist with Massachusetts General Hospital.
Dr Bardia discussed data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.
In DESTINY-Breast03, investigators found that fam-trastuzumab deruxtecan-nxki (Enhertu) significantly reduced the risk of progression or death compared with ado-trastuzumab emtansine (Kadcyla), results Bardia called practice changing.
Data from HER2CLIMB showed that trastuzumab (Herceptin) plus capecitabine (Xeloda) and tucatinib (Tukysa) extended overall survival by more than 9 months compared with capecitabine and trastuzumab alone.
NALA findings showed that neratinib (Nerlynx) plus capecitabine induced better outcomes in patients who received at least 2 previous HER2-directed treatment regimens compared with lapatinib (Tykerb) plus capecitabine.
Finally, Dr Bardia talked about upcoming results in breast cancer that he is looking forward to, including DESTINY-Breast04 (NCT03734029), TROPiCS-02 (NCT03901339), and persevERA Breast Cancer (NCT04546009).
Thank you for listening to this episode of OncLive On Air®, sponsored by Daiichi Sankyo. Check back on Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.